The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announces a Biomanufacturing Readiness Levels (BRLs) framework to lay the groundwork for a universal assessment of technology maturity and readiness level for commercial biomanufacturing technology adoption.
The BRL framework, described in the Biotechnology and...
Today, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced 32 coronavirus response projects to multiple organizations across the United States funded through the American Rescue Plan (ARP).
NIIMBL identified projects that will help the nation prevent, prepare for, and respond to coronavirus public health...
The United States Pharmacopeia (USP), the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) and The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), have announced a research collaboration to assess analytical methods and develop standards for adeno-associated virus (AAV), an...
The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) has made two awards totaling $153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The awards were announced today by U.S. Secretary of Commerce Gina Raimondo at the NIIMBL annual meeting in Washington, D.C.
NIIMBL...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a Manufacturing USA institute, announced that the University of Delaware, on behalf of NIIMBL, has entered into a Collaborative Research and Development Agreement (CRADA) with the Food and Drug Administration (FDA). Effective July 15, 2019, the FDA and NIIMBL will...
